XENON PHARMACEUTICALS INC. overview

Dover, Delaware--(Newsfile Corp. - October 16, 2019) - Encode Ideas, L.P. Initiates Research on Xenon Pharmaceuticals Inc. (NASDAQ: XENE). The full research publication is available here and available on our website at www.encodelp.com . A summary follows: Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on Xenon Pharmaceuticals (NASDAQ: XENE) as a high conviction idea. Xenon is at the forefront of a new wave of precision medicine in neurology,...

DGAP-News: Encode Ideas, LP / Key word(s): Miscellaneous Encode Ideas, L.P. Announces the Initiation of Research Coverage on Xenon Pharmaceuticals Inc. 16.10.2019 / 14:34 The issuer is solely responsible for the content of this announcement. Dover, Delaware--(Newsfile Corp. - October 16, 2019) - Encode Ideas, L.P. Initiates Research on Xenon Pharmaceuticals Inc. (NASDAQ: XENE). The full research publication is available here and available on our website at www.encodelp.com . A summary follows:...

NEW YORK, NY / ACCESSWIRE / May 9, 2017 / Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 4:30 PM Eastern Time. To listen to the event live - visit https://www.investornetwork.com/company/23196 . Replay Information The replay will be available online at https://www.investornetwork.com/company/23196 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of unique...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

BURNABY, British Columbia, Jan. 08, 2017 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today outlined its anticipated key corporate milestones for 2017. Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, “As we enter 2017, these upcoming quarters represent the most data-rich period in our history. We are looking forward to a number of important inflection points for our company: we expect topline data from our...

BURNABY, British Columbia, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Stifel 2016 Healthcare Conference in New York, NY on Tuesday, November 15, 2016 at 3:00 pm ET. A live audio webcast of the presentation will be available on the investors section of Xenon's website at www.xenon-pharma.com and...

BURNABY, British Columbia, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported its financial results for the quarter ended September 30, 2016 and provided a corporate update. Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, “We have continued our momentum with a strong quarter, which included the completion of a successful public offering that bolstered our balance sheet and supports our...